Results 61 to 70 of about 118,941 (325)

Research Models for Studying Vascular Calcification [PDF]

, 2020
Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen, Giet, Markus van der, Herrmann, Jaqueline, Schuchardt, Mirjam, Tölle, Markus   +4 more
core   +1 more source

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Cardiovascular Diabetology, 2023
Background As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults.
A. Goldman, B. Fishman, G. Twig, E. Raschi, T. Cukierman-Yaffe, Y. Moshkovits, Alon Pomerantz, I. Ben-Zvi, R. Dankner, E. Maor   +9 more
semanticscholar   +1 more source

Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control

Indian Journal of Endocrinology and Metabolism, 2019
Type 2 diabetes mellitus (T2DM) is a family of metabolic disorders characterized by hyperglycemia as a consequence of abnormalities in insulin secretion and insulin sensitivity. It affects hundreds of millions of people worldwide and leads to increased morbidity, compromised quality of life, higher mortality sodium glucose co-transporter 2 (SGLT2 ...
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal   +3 more
openaire   +3 more sources

Metabolic effects of sodium-glucose co-transporter 2 inhibitor

Clinical Endocrinology and Endocrine Surgery, 2022
The literature review considers the new universal molecule empagliflozin, which managed to change the glucose‑centric approach in endocrinology to an organoprotective one. The results of the pivotal clinical trials conducted with empagliflozin (EMPA‑REG‑OUTCOME, EMPEROR‑REDUCED, EMPEROR‑PRESERVED and EMPULSE) strongly support the ability of ...
openaire   +2 more sources

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Frontiers in Pharmacology, 2022
Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors play a key role in the treatment of type 2 diabetes mellitus.
Chen Li, Chen Li, Jie Luo, Jie Luo, Mingyan Jiang, Mingyan Jiang, Keke Wang, Keke Wang   +7 more
doaj   +1 more source

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes

Journal of Education, Health and Sport, 2022
Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski, Karolina Raksa, Ewelina Powroźniak, Karol Spozowski   +3 more
doaj   +1 more source

Lactate-proton co-transport and its contribution to interstitial acidification during hypoxia in isolated rat spinal roots [PDF]

, 1993
Exposure of nervous tissue to hypoxia results in interstitial acidification. There is evidence for concomitant decrease in extracellular pH to the increase in tissue lactate.
Aronson, Assaf, Ballanyi, Beaudry, Bonanno, Cabantchik, Chester, Combs, de Hemptinne, Deuticke, Deuticke, Dubinsky, Edlund, Grinstein, Halestrap, Halestrap, Halestrap, Halestrap, Halestrap, Hansen, Imai, Johnson, Juel, Kraig, Krnjević, Kuhr, Marrannes, Mason, Mutch, Poole, Poole, Poole, Poole, Raley-Susman, Roos, Roth, Scheller, Schneider, Schneider, Smith, Spencer, Strupp, Trosper, Walsh, Walz, Walz   +45 more
core   +1 more source

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance

ESC Heart Failure, 2022
Aims Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and ‘de novo’ acute heart failure (AHF) continue to experience unacceptably high post ...
João Pedro Ferreira, Joana Pimenta, Brenda Moura, Carlos Aguiar, Fátima Franco   +4 more
doaj   +1 more source

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Turkish Journal of Internal Medicine, 2021
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Hayri Bostan, Erman Çakal   +4 more
doaj   +1 more source

Iterative focused screening with biological fingerprints identifies selective Asc-1 inhibitors distinct from traditional high throughput screening [PDF]

, 2017
N-methyl-d-aspartate receptors (NMDARs) mediate glutamatergic signaling that is critical to cognitive processes in the central nervous system, and NMDAR hypofunction is thought to contribute to cognitive impairment observed in both schizophrenia and ...
Amoss, Adam, Cassaday, Jason A., Cooke, Andrew J., Culberson, J. Chris, Finley, Michael, Hermes, Jeffrey D., Hurzy, Danielle, Johnson, Eric N., Kutchukian, Peter S., Magliaro, Brian C., O’Donnell, Gregory, Parmentier-Batteur, Sophie, Pascarella, Danette, Schlegel, Kelly-Ann Sondra, Squadroni, Brian, Thomson, Fiona, Uebele, Victor N., Warren, Lee, Zuck, Paul   +18 more
core   +2 more sources